LAI-ART Awareness, Willingness, Barriers and Facilitators among Black Sexual Minority Men Living with HIV in the US South
Abstract
:1. Introduction
2. Methods
3. Results
3.1. LAI-ART Awareness and Knowledge
Recently, me and my friends, we’ve been talking about [HIV] because they’re getting this new shot that they have to take every month or every other month or something… You know, I heard about it from my doctor but knowing somebody who actually is doing the shot…(Jesse; 28; Detectable)
I heard of the shot. I think it’s in the butt... I have a friend that, he’s on it, and he’s a little bit older than me, but he takes the shot. He said at first it kinda hurt, it felt like a penicillin shot, but then he was like, when you start going, you get used to it. I think he said it’s like every eight weeks, and then it in both cheeks. He likes it, he said it’s better than taking medicine every day.(Brandon; 29; Undetectable)
3.2. LAI-ART Willingness
If it’s covered with insurance and if I’m able to get it at no cost, honestly, then I would be, I’d be down to do it. Because I’m pretty open to trying new things, that does sound a lot better than be having to take a pill every single day, I would be interested.(Jamar; 26; Undetectable)
I have heard of this, and I have wanted to know how to get in access or contact with the person that knows about this, because it sounds like something I want to try, because if it’ll take me off of pills, I’m down.(Edwin; 33; Undetectable)
I have questions because I want to know how is this once every two-month drug effective versus something that you’ve been taking every day or that you’ve had to take every day? Is it an extended release? Is it a higher dosage? Is it more potent, I guess? I don’t know. I’m like, okay, if it’s a stronger drug, because it has to be stronger if you’re going to be getting it once every two months.” So how is that going to affect you when you first get it? Are you going to have the downtime or what? So it’s questions that I have regarding that.(Anthony; 30; Undetectable)
That was something I wanted to talk to [my doctor] about. I just know I still want to give it maybe a couple more months, like eight months to a year, before I make a complete decision. I just want to see what goes on. They probably been testing this for a long time… I guess just to see how more people react to it. Versus just seeing what you see on TV and what you see on social media.(Jason; 34; Undetectable)
I’ve been on Triumeq for so long and it’s worked well with me for so long, I would just be leery, not anti, but leery of an injectable... My pill works. It took me a long time to get used to my pill and now I’m used to it and I know it agrees with me now. And I don’t have to worry about trying something new and worrying about it if it agrees with me or if I have to even go back to my pill.(Kevin; 28; Undetectable)
3.3. Barriers to LAI-ART Uptake
I inquired about it and my doctor told me I’ll never see it because she was like, “it costs so much that, there’s not going to be a program for it, and you’ll have to pay for it out of pocket, and it would just be expensive”, because I inquired about it… Yeah, because like we got Ryan White and then they got other stuff, then they got other programs that pay for the medicine, but she was like, when it comes down to that one, she was like, they don’t have a program for it.(Paul; 26; Detectable)
I’m trying to get it. My insurance doesn’t qualify for it, but I’m looking maybe for a study, or something. Something I want tomorrow if I could do it… So, they don’t approve the shot yet. So that’s all I’m waiting on.(Marcus; 30; Undetectable)
I’m not a fan of needles. I don’t like needles and stuff like that… I wonder how thick the needle is and the medication. I imagine there got to be a lot going inside of you at one time… If I heard a complication from a person, I’m not going to do it.(Mason; 31; Undetectable)
The reason why I haven’t started on it is because I don’t… The way my work schedule was, you only got so many days in between… So, I didn’t want to take that risk. So, once I can kind of get my work schedule down pat, then, yeah, I think that’s what I’ve been wanting to do.(George; 32; Undetectable)
I know I’ve been looking into this, you know, injection medicine, you know, that they started coming out with where you can go and get a shot once a month. It looks good, but I’m trying to—now my focus is I’m trying to get the medicine in my system so that—because they told me the only way I’ll be able to switch to an injectable, if it’s even available at a clinic I go to, is I have to get to undetectable first. That’s a requirement—so, that’s my focus now.(Phillip; 35; Detectable)
I like living free and just going about life without having to be, I guess you could say, responsible and take a pill every damn day or what have you… I would much rather move to, like, the injection once every three months or once every six months, but you have to get to undetectable in order to do that. But, yeah, just the whole pill idea feels restrictive to me because you have to keep them…(Jamal; 35; Detectable)
3.4. Motivators of LAI-ART Uptake
I just feel I would be undetectable. That’s all I want, want to make sure I wake up every day, and I’m undetectable. Because I know if I miss something, then I’d be worried… As long as I hear I’m undetectable that I’m happy, that’s all I want. That’s all I want to hear. And I think if I get the shot, I’ll be fully undetectable, I think.(Marcus; 30; Undetectable)
You know I wouldn’t mind doing it, due to, there are days that I do forget to take my medicine or there are days where I go out and I binge, and I don’t have my medicine with me. So, you know, that would be very beneficial. But I’m always like worried about the side effects or what’s going to happen to me.(Keith; 30; Undetectable)
I feel like it would be easier for me to go to my doctor and get my shot, you know, once a month or whatever frequency they want me to. It’s easier that way for me. And then I wouldn’t have to remember every day. And then, some days, you know, when I’m sick it’s like I don’t even want to get up out the bed.(Philip; 35; Detectable)
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Centers for Disease Control and Prevention. HIV Surveillance Report 2019; U.S. Department of Health and Human Services: Atlanta, GA, USA, 2021.
- Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas, 2019; HIV Surveillance Supplemental Report 2021; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2021.
- Buchacz, K.; Armon, C.; Tedaldi, E.; Palella, F.J., Jr.; Novak, R.M.; Ward, D.; Hart, R.; Durham, M.D.; Brooks, J.T.; HIV Outpatient Study Investigators. Disparities in HIV viral load suppression by race/ethnicity among men who have sex with men in the HIV outpatient study. AIDS Res. Hum. Retroviruses 2018, 34, 357–364. [Google Scholar] [CrossRef]
- Fedonni, D.; Buendia, J.R.; Sears, S.C.; Vaaler, M.L.; Mgbere, O.O. Factors Associated with ART Adherence among MSM Receiving Medical Care in Texas: An Analysis of the Texas Medical Monitoring Project Data. J. Behav. Health 2021, 10, 1–10. [Google Scholar] [CrossRef]
- Shubber, Z.; Mills, E.J.; Nachega, J.B.; Vreeman, R.; Freitas, M.; Bock, P.; Nsanzimana, S.; Penazzato, M.; Appolo, T.; Doherty, M.; et al. Patient-reported barriers to adherence to antiretroviral therapy: A systematic review and meta-analysis. PLoS Med. 2016, 13, e1002183. [Google Scholar] [CrossRef]
- Tan, J.Y.; Campbell, C.K.; Conroy, A.A.; Tabrisky, A.P.; Kegeles, S.; Dworkin, S.L. Couple-Level Dynamics and Multilevel Challenges Among Black Men Who Have Sex With Men: A Framework of Dyadic HIV Care. AIDS Patient Care STDS 2018, 32, 459–467. [Google Scholar] [CrossRef]
- Kerrigan, D.; Mantsios, A.; Gorgolas, M.; Montes, M.-L.; Pulido, F.; Brinson, C.; Devente, J.; Richmond, G.J.; Beckham, S.W.; Hammond, P.; et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir+ rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE 2018, 13, e0190487. [Google Scholar] [CrossRef]
- Boroughs, M.S.; Valentine, S.E.; Ironson, G.H.; Shipherd, J.C.; Safren, S.A.; Taylor, S.W.; Dale, S.K.; Baker, J.S.; Wilner, J.G.; O’cleirigh, C. Complexity of childhood sexual abuse: Predictors of current post-traumatic stress disorder, mood disorders, substance use, and sexual risk behavior among adult men who have sex with men. Arch. Sex. Behav. 2015, 44, 1891–1902. [Google Scholar] [CrossRef]
- Quinn, K.G.; Voisin, D.R. ART adherence among men who have sex with men living with HIV: Key challenges and opportunities. Curr. HIV/AIDS Rep. 2020, 17, 290–300. [Google Scholar] [CrossRef]
- Ramos, S.D.; Vincent, W.; Siconolfi, D.E.; Pollack, L.M.; Horvath, K.J.; Campbell, C.K.; Tebbetts, S.; Kegeles, S.M.; Storholm, E.D. Differential associations of depressive symptomology to HIV care engagement among young black sexual minority men with HIV (YBSMM+) in the US South: A multi-group analysis of mood, intimate partner violence, and alcohol use. AIDS Behav. 2023, 28, 774–785. [Google Scholar] [CrossRef]
- Quinn, K.G.; Spector, A.; Takahashi, L.; Voisin, D.R. Conceptualizing the effects of continuous traumatic violence on HIV continuum of care outcomes for young Black men who have sex with men in the United States. AIDS Behav. 2021, 25, 758–772. [Google Scholar] [CrossRef]
- Quinn, K.G.; Reed, S.J.; Dickson-Gomez, J.; Kelly, J.A. An exploration of syndemic factors that influence engagement in HIV care among Black men. Qual. Health Res. 2018, 28, 1077–1087. [Google Scholar] [CrossRef]
- Sweeney, S.M.; Vanable, P.A. The association of HIV-related stigma to HIV medication adherence: A systematic review and synthesis of the literature. AIDS Behav. 2016, 20, 29–50. [Google Scholar] [CrossRef]
- Rao, D.; Kekwaletswe, T.; Hosek, S.; Martinez, J.; Rodriguez, F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care 2007, 19, 28–33. [Google Scholar] [CrossRef]
- Rintamaki, L.; Kosenko, K.; Hogan, T.; Scott, A.M.; Dobmeier, C.; Tingue, E.; Peek, D. The role of stigma management in HIV treatment adherence. Int. J. Environ. Res. Public Health 2019, 16, 5003. [Google Scholar] [CrossRef]
- Kanazawa, J.T.; Saberi, P.; Sauceda, J.A.; Dubé, K. The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review. AIDS Res. Hum. Retroviruses 2020, 37, 75–88. [Google Scholar] [CrossRef]
- Jolayemi, O.; Bogart, L.M.; Storholm, E.D.; Goodman-Meza, D.; Rosenberg-Carlson, E.; Cohen, R.; Kao, U.; Shoptaw, S.; Landovitz, R.J. Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS ONE 2022, 17, e0262926. [Google Scholar] [CrossRef]
- Campbell, C.K.; Dube, K.; Sauceda, J.A.; Ndukwe, S.; Saberi, P. Antiretroviral therapy experience, satisfaction, and preferences among a diverse sample of young adults living with HIV. AIDS Care 2022, 34, 1212–1218. [Google Scholar] [CrossRef]
- D’Amico, R.; Margolis, D.A. Long-acting injectable therapy: An emerging paradigm for the treatment of HIV infection. Curr. Opin. HIV AIDS 2020, 15, 13–18. [Google Scholar] [CrossRef]
- Dubé, K.; Eskaf, S.; Evans, D.; Sauceda, J.; Saberi, P.; Brown, B.; Averitt, D.; Martel, K.; Meija, M.; Campbell, D.; et al. The dose response: Perceptions of people living with HIV in the United States on alternatives to oral daily antiretroviral therapy. AIDS Res. Hum. Retroviruses 2020, 36, 324–348. [Google Scholar] [CrossRef]
- Balasubramanian, R.; Kasaie, P.; Schnure, M.; Dowdy, D.W.; Shah, M.; Fojo, A.T. Projected impact of expanded long-acting injectable PrEP use among men who have sex with men on local HIV epidemics. JAIDS J. Acquir. Immune Defic. Syndr. 2022, 91, 144–150. [Google Scholar] [CrossRef]
- Holloway, I.; Dougherty, R.; Gildner, J.; Beougher, S.C.; Pulsipher, C.; Montoya, J.A.; Plant, A.; Leibowitz, A. PrEP uptake, adherence, and discontinuation among California YMSM using geosocial networking applications. J. Acquir. Immune Defic. Syndr. 2017, 74, 15–20. [Google Scholar] [CrossRef]
- Tran, N.K.; Martinez, O.; Scheim, A.I.; Goldstein, N.D.; Welles, S.L. Perceived Barriers to and Facilitators of Long-Acting Injectable HIV PrEP Use Among Black, Hispanic/Latino, and White Gay, Bisexual, and Other Men Who Have Sex with Men. AIDS Educ. Prev. 2022, 34, 365–378. [Google Scholar] [CrossRef]
- Watson, R.J.; Morgan, E.; Sherman, J.; Caba, A.E.; Wheldon, C.W.; Chan, P.A.; Eaton, L.A. Pre-exposure prophylaxis (PrEP) use, anticipated PrEP stigma, and bisexual identity among a Black and Hispanic/Latino sexual and gender diverse sample. Behav. Med. 2023, 49, 283–291. [Google Scholar] [CrossRef]
- Wray, T.B.; Chan, P.A.; Klausner, J.D.; Ward, L.M.; Ocean, E.M. Gay, bisexual, and other men who have sex with men who are not on oral PrEP may be less interested in available injectable products than in oral PrEP: Examining individual-level determinants of interest and barriers across products. AIDS Behav. 2022, 26, 3794–3805. [Google Scholar] [CrossRef]
- Cooper, S.E.; Rosenblatt, J.; Gulick, R.M. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of Human Immunodeficiency Virus (HIV) in high-income countries. Clin. Infect. Dis. 2022, 75 (Suppl. S4), S541–S548. [Google Scholar] [CrossRef]
- Coombs, A.; McFarland, W.; Ick, T.; Fuqua, V.; Buchbinder, S.P.; Fuchs, J.D. Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial. J. Acquir. Immune Defic. Syndr. 2014, 66, e94–e97. [Google Scholar] [CrossRef]
- Storholm, E.D.; Siconolfi, D.E.; Campbell, C.K.; Pollack, L.M.; Kegeles, S.M.; Rebchook, G.M.; Tebbetts, S.; Vincent, W. Structural Inequities, Syndemics, and Resilience: The Critical Role of Social Support in Overcoming Barriers and Empowering Engagement in HIV Care for Young Black Sexual-Minority Men in the US South. J. Racial Ethn. Health Disparities 2023, 1–12. [Google Scholar] [CrossRef]
- Vincent, W.; Siconolfi, D.E.; Pollack, L.; Campbell, C.K.; Kegeles, S.M.; Storholm, E.D. What’s in Your Dataset? Measuring Engagement in HIV Care Using Routinely Administered Items with a Population Disproportionately Burdened by HIV. AIDS Behav. 2023, 28, 1423–1434. [Google Scholar] [CrossRef]
- Malterud, K.; Siersma, V.D.; Guassora, A.D. Sample size in qualitative interview studies: Guided by information power. Qual. Health Res. 2016, 26, 1753–1760. [Google Scholar] [CrossRef]
- Braun, V.; Clarke, V.; Hayfield, N.; Davey, L.; Jenkinson, E. Doing reflexive thematic analysis. In Supporting Research in Counselling and Psychotherapy: Qualitative, Quantitative, and Mixed Methods Research; Springer: Berlin/Heidelberg, Germany, 2023; pp. 19–38. [Google Scholar]
- Braun, V.; Clarke, V. Conceptual and design thinking for thematic analysis. Qual. Psychol. 2022, 9, 3. [Google Scholar] [CrossRef]
- Braun, V.; Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3, 77–101. [Google Scholar] [CrossRef]
- Braun, V.; Clarke, V. Is thematic analysis used well in health psychology? A critical review of published research, with recommendations for quality practice and reporting. Health Psychol. Rev. 2023, 17, 695–718. [Google Scholar] [CrossRef]
- King, N.; Brooks, J. Thematic analysis in organisational research. In The SAGE Handbook of Qualitative Business and Management Research Methods: Methods and Challenges; Sage: Thousand Oaks, CA, USA, 2018; pp. 219–236. [Google Scholar]
- Goedel, W.C.; Nunn, A.S.; Chan, P.A.; Duncan, D.T.; Biello, K.B.; Safren, S.A.; Marshall, B.D. A shot at equity? Addressing disparities among Black MSM in the coming era of long-acting injectable preexposure prophylaxis. AIDS 2019, 33, 2110. [Google Scholar] [CrossRef]
- Levy, M.E.; Patrick, R.; Gamble, J.; Rawls, A.; Opoku, J.; Magnus, M.; Kharfen, M.; Greenberg, A.E.; Kuo, I. Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis. PLoS ONE 2017, 12, e0183521. [Google Scholar] [CrossRef]
- Patel, R.R.; Crane, J.S.; López, J.; Chan, P.A.; Liu, A.Y.; Tooba, R.; James, A.S. Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. PLoS ONE 2018, 13, e0209484. [Google Scholar] [CrossRef]
- Simoni, J.M.; Beima-Sofie, K.; Mohamed, Z.H.; Christodoulou, J.; Tapia, K.; Graham, S.M.; Ho, R.; Collier, A.C. Long-acting injectable antiretroviral treatment acceptability and preferences: A qualitative study among US providers, adults living with HIV, and parents of youth living with HIV. AIDS Patient Care STDS 2019, 33, 104–111. [Google Scholar] [CrossRef]
- Eaton, L.A.; Driffin, D.D.; Kegler, C.; Smith, H.; Conway-Washington, C.; White, D.; Cherry, C. The role of stigma and medical mistrust in the routine health care engagement of black men who have sex with men. Am. J. Public Health 2015, 105, e75–e82. [Google Scholar] [CrossRef]
- Meyers-Pantele, S.A.; Sullivan, P.; Mansergh, G.; Hirshfield, S.; Stephenson, R.; Horvath, K.J. Race-based medical mistrust, HIV-related stigma, and ART adherence in a diverse sample of men who have sex with men with HIV. AIDS Behav. 2021, 26, 1456–1466. [Google Scholar] [CrossRef]
- Orkin, C.; Arasteh, K.; Górgolas Hernández-Mora, M.; Pokrovsky, V.; Overton, E.T.; Girard, P.-M.; Oka, S.; Walmsley, S.; Bettacchi, C.; Brinson, C.; et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med. 2020, 382, 1124–1135. [Google Scholar] [CrossRef] [PubMed]
- Overton, E.T.; Richmond, G.; Rizzardini, G.; Jaeger, H.; Orrell, C.; Nagimova, F.; Bredeek, F.; Deltoro, M.G.; Swindells, S.; Andrade-Villanueva, J.F.; et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 2020, 396, 1994–2005. [Google Scholar] [CrossRef]
- Swindells, S.; Andrade-Villanueva, J.-F.; Richmond, G.J.; Rizzardini, G.; Baumgarten, A.; Masiá, M.; Latiff, G.; Pokrovsky, V.; Bredeek, F.; Smith, G.; et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N. Engl. J. Med. 2020, 382, 1112–1123. [Google Scholar] [CrossRef]
- Christopoulos, K.A.; Grochowski, J.; Mayorga-Munoz, F.; Hickey, M.D.; Imbert, E.; Szumowski, J.D.; Dilworth, S.; Oskarsson, J.; Shiels, M.; Havlir, D.; et al. First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic. Clin. Infect. Dis. 2023, 76, e645–e651. [Google Scholar] [CrossRef] [PubMed]
- Gandhi, M.; Hickey, M.; Imbert, E.; Grochowski, J.; Mayorga-Munoz, F.; Szumowski, J.D.; Oskarsson, J.; Shiels, M.; Sauceda, J.; Salazar, J.; et al. Demonstration project of long-acting antiretroviral therapy in a diverse population of people with, H.I.V. Ann. Intern. Med. 2023, 176, 969–974. [Google Scholar] [CrossRef] [PubMed]
- Texas Health and Human Services. Texas HIV Medication Program (THMP) Medication Formulary and Maximum Quantities 2023. [Updated September 2023]. Available online: https://www.dshs.texas.gov/sites/default/files/hivstd/meds/files/Formulary2.pdf (accessed on 10 December 2023).
- Programs DoADA. ADAP Directory: Texas 2023. Available online: https://adap.directory/texas#cab (accessed on 10 December 2023).
- Meyers, K.; Wu, Y.; Brill, A.; Sandfort, T.; Golub, S.A. To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience. PLoS ONE 2018, 13, e0200296. [Google Scholar] [CrossRef]
- Xavier Hall, C.D.; Smith, J.C.; Driggers, R.A.; Stoller, B.; Khan, Z.; Li, J.; Ignatius, E.; Siegler, A.J. PrEParing for long-acting injectable PrEP in the South: Perspectives from healthcare providers in Georgia. AIDS Care 2021, 33, 706–711. [Google Scholar] [CrossRef]
n | % | ||||
---|---|---|---|---|---|
Age Mean | 30.81 | HIV Viral Load | |||
Median | 31 | Undetectable | 21 | 78% | |
Range | 26–35 | Detectable | 5 | 19% | |
Don’t Know | 1 | 4% | |||
Time Since HIV Diagnosis (Years) | |||||
Mean | 10.85 | Currently on ART? | |||
Median | 10 | Yes | 23 | 85% | |
Range | 6–17 | No | 4 | 15% | |
n | % | On ART for Past 60 days | 22 | 81% | |
Education | |||||
High school diploma or GED | 7 | 26% | Number of Days Missed ART Doses (Past 60 Days) ** | ||
Some college, associate degree | 14 | 52% | Never | 6 | 27% |
Bachelor’s degree | 4 | 15% | Less than once a week | 4 | 18% |
Any graduate studies | 2 | 7% | Once a week | 2 | 9% |
2–3 days a week | 6 | 27% | |||
Sexual Identity | 4–6 days a week | 1 | 5% | ||
Gay | 21 | 78% | Every day | 3 | 14% |
Bisexual | 6 | 22% | |||
Income | Missed ART ≥7 Consecutive Days (Past 12 months)? ± | ||||
Less than USD 10,000 | 6 | 22% | Yes | 6 | 26% |
USD 10,000–19,999 | 4 | 15% | No | 17 | 74% |
USD 20,000–39,999 | 6 | 22% | |||
USD 40,000–59,999 | 6 | 22% | Ever Experienced a Relationship with IPV ^ | ||
USD 60,000–79,999 | 2 | 7% | Yes | 17 | 77% |
Decline to Answer | 1 | 4% | No | 5 | 23% |
Don’t know | 2 | 7% | |||
Substance Use (Past 60 Days) | |||||
Insurance Status | Cocaine | 6 | 22% | ||
Yes | 19 | 70% | Prescription Stimulants | 7 | 26% |
No | 7 | 26% | Meth | 9 | 33% |
Unknown | 1 | 4% | Inhalants | 3 | 11% |
Sedatives/Sleeping Pills | 4 | 15% | |||
Employment | Hallucinogens | 3 | 11% | ||
Full Time | 12 | 44% | Street Opioids | 2 | 7% |
Part-Time | 4 | 15% | Prescription Opioids | 2 | 7% |
Unemployed | 11 | 41% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Campbell, C.K.; Kielhold, K.; Reynolds, H.E.; Vincent, W.; Siconolfi, D.E.; Ramos, S.D.; Ogunbajo, A.; Kegeles, S.M.; Storholm, E.D. LAI-ART Awareness, Willingness, Barriers and Facilitators among Black Sexual Minority Men Living with HIV in the US South. Int. J. Environ. Res. Public Health 2024, 21, 602. https://doi.org/10.3390/ijerph21050602
Campbell CK, Kielhold K, Reynolds HE, Vincent W, Siconolfi DE, Ramos SD, Ogunbajo A, Kegeles SM, Storholm ED. LAI-ART Awareness, Willingness, Barriers and Facilitators among Black Sexual Minority Men Living with HIV in the US South. International Journal of Environmental Research and Public Health. 2024; 21(5):602. https://doi.org/10.3390/ijerph21050602
Chicago/Turabian StyleCampbell, Chadwick K., Kirstin Kielhold, Hannah E. Reynolds, Wilson Vincent, Daniel E. Siconolfi, Stephen D. Ramos, Adedotun Ogunbajo, Susan M. Kegeles, and Erik D. Storholm. 2024. "LAI-ART Awareness, Willingness, Barriers and Facilitators among Black Sexual Minority Men Living with HIV in the US South" International Journal of Environmental Research and Public Health 21, no. 5: 602. https://doi.org/10.3390/ijerph21050602